Runx2 in normal tissues and cancer cells: A developing story

Blood Cells, Molecules, and Diseases

Volumn 45, Issue 2, 2010, Pages 117-123

  Blyth, Karen ^a   Vaillant, Francois ^b   Jenkins, Alma ^b   McDonald, Laura ^a   Pringle, Marie Anne ^b   Huser, Camille ^b   Stein, Torsten ^b   Neil, James ^b   Cameron, Ewan R ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Haematopoietic; Mammary; Oncogene; Prostate; Runx

Indexed keywords

BETA CASEIN; COLLAGENASE 3; ESTROGEN RECEPTOR; GELATINASE B; HERMES ANTIGEN; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE PIM 1; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; UVOMORULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CARCINOGENESIS; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL LYMPHOMA; TUMOR PROMOTION;

ANIMALS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; GENES, TUMOR SUPPRESSOR; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ONCOGENES;

MAMMALIA;

EID: 77955271025     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.05.007     Document Type: Article

References (76)

1. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 2005, 5:376-387.
2. Stewart M., Terry A., O'Hara M., et al. til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. J. Gen. Virol. 1996, 77(Pt 3):443-446.
3. Stewart M., Terry A., Hu M., et al. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc. Nat. Acad. Sci. U.S.A. 1997, 94:8646-8651.
4. Vaillant F., Blyth K., Terry A., et al. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 1999, 18:7124-7134.
5. Blyth K., Terry A., Mackay N., et al. Runx2: a novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 2001, 20:295-302.
6. Blyth K., Vaillant F., Hanlon L., et al. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res. 2006, 66:2195-2201.
7. Castilla L.H., Perrat P., Martinez N.J., et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:4924-4929.
8. Adya N., Stacy T., Speck N.A., Liu P.P. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol. Cell Biol. 1998, 18:7432-7443.
9. Lutterbach B., Hou Y., Durst K.L., Hiebert S.W. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:12822-12827.
10. Durst K.L., Lutterbach B., Kummalue T., et al. The inv(16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain. Mol. Cell Biol. 2003, 23:607-619.
11. Kuo Y.H., Zaidi S.K., Gornostaeva S., et al. Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice. Blood 2009, 113:3323-3332.
12. Vaillant F., Blyth K., Andrew L., et al. Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J. Immunol. 2002, 169:2866-2874.
13. Ichikawa M., Asai T., Saito T., et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat. Med. 2004, 10:299-304.
14. Growney J.D., Shigematsu H., Li Z., et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005, 106:494-504.
15. Wang C.Q., Jacob B., Nah G.S., Osato M. Runx family genes, niche, and stem cell quiescence. Blood Cells Mol. Dis. 2010, 44:275-286.
16. Morrow M., Samanta A., Kioussis D., et al. TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene 2007, 26:4404-4414.
17. Okumura A.J., Peterson L.F., Lo M.C., Zhang D.E. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells. Exp. Hematol. 2007, 35:978-988.
18. Ehrhardt G.R., Hijikata A., Kitamura H., et al. Discriminating gene expression profiles of memory B cell subpopulations. J. Exp. Med. 2008, 205:1807-1817.
19. Dijkman R., van Doorn R., Szuhai K., et al. Gene-expression profiling and array-based CGH classify CD4+ CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities. Blood 2007, 109:1720-1727.
20. Colla S., Morandi F., Lazzaretti M., et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005, 19:2166-2176.
21. Roodman G.D. Pathogenesis of myeloma bone disease. J. Cell Biochem. 2010, 109:283-291.
22. Levanon D., Brenner O., Negreanu V., et al. Spatial and temporal expression pattern of Runx3 (Aml2) and Runx1 (Aml1) indicates non-redundant functions during mouse embryogenesis. Mech. Dev. 2001, 109:413-417.
23. Sakuma A., Fukamachi H., Ito K., et al. Loss of Runx3 affects ovulation and estrogen-induced endometrial cell proliferation in female mice. Mol. Reprod. Dev. 2008, 75:1653-1661.
24. Planaguma J., Diaz-Fuertes M., Gil-Moreno A., et al. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma. Cancer Res. 2004, 64:8846-8853.
25. Doll A., Gonzalez M., Abal M., et al. An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis. Int. J. Cancer 2009, 125:257-263.
26. Konno R., Fujiwara H., Netsu S., et al. Gene expression profiling of the rat endometriosis model. Am. J. Reprod. Immunol. 2007, 58:330-343.
27. Luo X., Ding L., Xu J., Chegini N. Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinology 2005, 146:1097-1118.
28. McRae R.S., Johnston H.M., Mihm M., O'Shaughnessy P.J. Changes in mouse granulosa cell gene expression during early luteinization. Endocrinology 2005, 146:309-317.
29. Jo M., Gieske M.C., Payne C.E., et al. Development and application of a rat ovarian gene expression database. Endocrinology 2004, 145:5384-5396.
30. Jo M., Curry T.E. Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. Mol. Endocrinol. 2006, 20:2156-2172.
31. Jeong J.H., Jin J.S., Kim H.N., et al. Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain. J. Cell Physiol. 2008, 217:511-517.
32. Park E.S., Lind A.K., Dahm-Kahler P., et al. RUNX2 transcription factor regulates gene expression in luteinizing granulosa cells of rat ovaries. Mol. Endocrinol. 2010, 24:846-858.
33. Li F., Liu J., Park E.S., et al. The B cell translocation gene (BTG) family in the rat ovary: hormonal induction, regulation, and impact on cell cycle kinetics. Endocrinology 2009, 150:3894-3902.
34. Liu J., Park E.S., Curry T.E., Jo M. Periovulatory expression of hyaluronan and proteoglycan link protein 1 (Hapln1) in the rat ovary: hormonal regulation and potential function. Mol. Endocrinol. 2010, 24:1203-1217.
35. Otto F., Thornell A.P., Crompton T., et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771.
36. Kouros-Mehr H., Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev. Dyn. 2006, 235:3404-3412.
37. Inman C.K., Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J. Biol. Chem. 2003, 278:48684-48689.
38. Inman C.K., Li N., Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol. Cell Biol. 2005, 25:3182-3193.
39. Watson C.J., Khaled W.T. Mammary development in the embryo and adult: a journey of morphogenesis and commitment. Development 2008, 135:995-1003.
40. Kendrick H., Regan J.L., Magnay F.A., et al. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 2008, 9:591.
41. Shackleton M., Vaillant F., Simpson K.J., et al. Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
42. Stingl J., Eirew P., Ricketson I., et al. Purification and unique properties of mammary epithelial stem cells. Nature 2006, 439:993-997.
43. Lau Q.C., Raja E., Salto-Tellez M., et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006, 66:6512-6520.
44. Nagaraja G.M., Othman M., Fox B.P., et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006, 25:2328-2338.
45. Pratap J., Javed A., Languino L.R., et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol. Cell Biol. 2005, 25:8581-8591.
46. Javed A., Barnes G.L., Pratap J., et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Nat. Acad. Sci. U.S.A. 2005, 102:1454-1459.
47. Pratap J., Imbalzano K.M., Underwood J.M., et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res. 2009, 69:6807-6814.
48. Barnes G.L., Hebert K.E., Kamal M., et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004, 64:4506-4513.
49. Khalid O., Baniwal S.K., Purcell D.J., et al. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. Endocrinology 2008, 149:5984-5995.
50. Das K., Leong D.T., Gupta A., et al. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur. J. Cancer 2009, 45:2239-2248.
51. Fowler M., Borazanci E., McGhee L., et al. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J. Cell Biochem. 2006, 97:1-17.
52. Nadiminty N., Lou W., Lee S.O., et al. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin. Cancer Res. 2006, 12:1420-1430.
53. Chua C.W., Chiu Y.T., Yuen H.F., et al. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin. Cancer Res. 2009, 15:4322-4335.
54. Akech J., Wixted J.J., Bedard K., et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821.
55. Butterworth K.T., McCarthy H.O., Devlin A., et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant geno- and phenotype. Int. J. Cancer 2008, 123:760-768.
56. Lim M., Zhong C., Yang S., et al. Runx2 regulates survivin expression in prostate cancer cells. Lab. Invest. 2010, 90:222-233.
57. Banach-Petrosky W., Jessen W.J., Ouyang X., et al. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice. Cancer Res. 2007, 67:9089-9096.
58. Fujii M., Hayashi K., Niki M., et al. Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis. Oncogene 1998, 17:1813-1820.
59. Abe N., Kohu K., Ohmori H., et al. Reduction of Runx1 transcription factor activity up-regulates Fas and Bim expression and enhances the apoptotic sensitivity of double positive thymocytes. J. Immunol. 2005, 175:4475-4482.
60. Wotton S., Terry A., Kilbey A., et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008, 27:5856-5866.
61. Diakos C., Krapf G., Gerner C., et al. RNAi-mediated silencing of TEL/AML1 reveals a heat-shock protein- and survivin-dependent mechanism for survival. Blood 2007, 109:2607-2610.
62. Balkhi M.Y., Christopeit M., Chen Y., et al. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation. Exp. Hematol. 2008, 36:1449-1460.
63. Selvamurugan N., Chou W.Y., Pearman A.T., et al. Parathyroid hormone regulates the rat collagenase-3 promoter in osteoblastic cells through the cooperative interaction of the activator protein-1 site and the runt domain binding sequence. J. Biol. Chem. 1998, 273:10647-10657.
64. Jimenez M.J., Balbin M., Lopez J.M., et al. Collagenase 3 is a target of Cbfa1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell Biol. 1999, 19:4431-4442.
65. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
66. Sato M., Morii E., Komori T., et al. Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. Oncogene 1998, 17:1517-1525.
67. Shen Q., Christakos S. The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J. Biol. Chem. 2005, 280:40589-40598.
68. Desai B., Ma T., Zhu J., Chellaiah M.A. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J. Cell Biochem. 2009, 108:272-284.
69. Josson S., Matsuoka Y., Chung L.W., et al. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 2010, 21:26-32.
70. Cher M.L. Mechanisms governing bone metastasis in prostate cancer. Curr. Opin. Urol. 2001, 11:483-488.
71. Koeneman K.S., Yeung F., Chung L.W. Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 1999, 39:246-261.
72. Lin D.L., Tarnowski C.P., Zhang J., et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001, 47:212-221.
73. Yeung F., Law W.K., Yeh C.H., et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J. Biol. Chem. 2002, 277:2468-2476.
74. Brubaker K.D., Vessella R.L., Brown L.G., Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22.
75. Yin J.J., Selander K., Chirgwin J.M., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 1999, 103:197-206.
76. Barnes G.L., Javed A., Waller S.M., et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res. 2003, 63:2631-2637.